When India’s Supreme Court ruled this week that Novartis AG’s cancer drug Gleevec was not sufficiently innovative to merit a patent, public health advocates lauded the decision, which they said would give more people access to needed drugs, and Big Pharma condemned it, saying it would stifle innovation.
The court’s decision, however, was not about encouraging innovation or access. It revolved around a practice the pharmaceutical industry refers to as "life-cycle management" and which public health advocates call "evergreening."
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
